Is Vaginal Delivery Safe in Pregnancies at Risk of FNAIT?

Managing childbirth in mothers with human platelet antigen alloimmunisation poses major clinical dilemmas. Clinicians often question the safety of vaginal delivery in FNAIT pregnancies due to fears of intracranial haemorrhage. However, recent evidence suggests that antenatal intravenous immunoglobulin therapy significantly mitigates neonatal bleeding risks.

Evaluating Vaginal Delivery in FNAIT and Neonatal Safety

Historically, clinicians frequently chose elective caesarean sections to prevent traumatic neonatal haemorrhage. Therefore, obstetricians often avoided vaginal births in sensitised mothers. Nevertheless, antenatal intravenous immunoglobulin (IVIG) has altered this clinical landscape. Researchers evaluated 73 subsequent pregnancies affected by human platelet antigen alloimmunisation in the Netherlands. Notably, 72 of these pregnancies received weekly antenatal IVIG therapy. The study cohort included 16 high-risk and 57 standard-risk pregnancies. Consequently, these findings offer essential real-world insight into neonatal bleeding risks across delivery modes.

Bleeding Complications and Platelet Counts by Delivery Mode

The study results revealed encouraging outcomes for infants delivered vaginally. Across the entire cohort, 44 mothers delivered vaginally. Remarkably, not a single infant delivered vaginally developed intracranial haemorrhage. Among the 16 high-risk pregnancies, six delivered vaginally and 10 underwent caesarean delivery. Although two vaginally delivered neonates had severe thrombocytopenia below 50 × 10^9/L, none experienced bleeding complications. Similarly, four infants born via caesarean section in the high-risk group had platelet counts below 50 × 10^9/L without haemorrhage. In the standard-risk cohort, 38 women had vaginal deliveries, resulting in 13 neonates with platelet counts below 50 × 10^9/L. Furthermore, only one infant in this vaginal group showed mild petechiae. In contrast, among the 19 standard-risk caesarean births, three neonates developed petechiae or haematomas. Additionally, clinicians identified one antenatal intracranial haemorrhage before IVIG initiation. Thus, vaginal birth did not elevate the incidence of severe bleeding.

Clinical Implications for Obstetric and Neonatal Practice

These clinical findings provide reassurance for obstetric teams managing sensitized pregnancies. For decades, practitioners feared that mechanical forces during labour would precipitate fetal intracranial bleeding. However, this cohort demonstrates that effective antenatal IVIG treatment confers substantial protection. Clinicians can consider vaginal delivery as a viable option in well-monitored, IVIG-treated pregnancies. Nevertheless, delivery teams must avoid invasive intrapartum procedures, including fetal scalp electrodes and vacuum extraction. Moreover, pediatric units must arrange immediate cord blood platelet testing and have compatible platelets readily available at birth. In conclusion, multidisciplinary care between maternal-fetal medicine specialists and neonatologists ensures safe perinatal management.

Frequently Asked Questions

Q1: Does vaginal delivery increase the risk of intracranial haemorrhage in FNAIT?

No, evidence indicates that vaginal delivery does not elevate intracranial haemorrhage risk in mothers receiving antenatal intravenous immunoglobulin.

Q2: Why is antenatal IVIG therapy critical in managing pregnancies affected by FNAIT?

Antenatal IVIG suppresses maternal antibody-mediated destruction of fetal platelets. Consequently, it protects the fetus against severe bleeding and intracranial haemorrhage.

Q3: What precautions are essential during labour in known FNAIT pregnancies?

Clinicians must avoid vacuum extractors, forceps, and fetal scalp electrodes. Furthermore, teams must ensure rapid access to matched platelets.

References

1. Pothof R et al. Mode of Birth and Bleeding Outcomes in Pregnancies at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia: A Retrospective Cohort Study. BJOG. 2026 Nov 08. doi: 10.1111/1471-0528.70371. PMID: 43000046.
2. Royal College of Obstetricians and Gynaecologists. Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT). Scientific Impact Paper No. 61. 2019.
3. Winkelhorst D, Murphy MF, Greinacher A, et al. Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. Blood. 2017;129(11):1538-1547.